文献速递淋巴瘤

初治滤泡性淋巴瘤患者接受CHOP联合利妥昔单抗或CHOP联合碘-131托西莫单抗治疗后的持续优异结局:III期随机研究SWOG-S0016的长期随访

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
PubMed 文献 · J Clin Oncol · 2018-01-22

SWOG-S0016是一项III期随机研究,2001年至2008年入组531例初治滤泡性淋巴瘤患者,随机接受六周期R-CHOP或CHOP-RIT。中位随访10.3年,CHOP-RIT组10年无进展生存优于R-CHOP组(56%对42%,P=0.01),但10年总生存无差异(75%对81%,P=0.13)。

要点

  • CHOP-RIT组10年无进展生存显著优于R-CHOP组(56%对42%,P=0.01)。
  • 两组10年总生存无显著差异(CHOP-RIT 75%对R-CHOP 81%,P=0.13)。
  • CHOP-RIT组继发MDS/AML的10年累积死亡发生率高于R-CHOP组(4%对0.9%,P=0.02)。

核心结论

  • 鉴于这些优异结局,在替代方法的长期随访证明优效之前,免疫化疗应继续作为高危滤泡性淋巴瘤患者的标准诱导方案。

研究设计与样本

  • SWOG S0016是一项III期随机研究,2001年至2008年入组531例初治滤泡性淋巴瘤患者,随机接受六周期R-CHOP或六周期CHOP-RIT。
  • 入组患者为晚期疾病(大块II期、III期或IV期),病理分级为1、2或3级。

主要发现

  • 中位随访10.3年,全部患者的10年无进展生存和总生存估计分别为49%和78%。
  • CHOP-RIT组10年无进展生存显著优于R-CHOP组(56%对42%,P=0.01)。
  • 两组10年总生存无差异(CHOP-RIT 75%对R-CHOP 81%,P=0.13)。
  • 两组第二恶性肿瘤发生率无显著差异(CHOP-RIT 15.1%对R-CHOP 16.1%,P=0.81),MDS或AML发生率也无显著差异(CHOP-RIT 4.9%对R-CHOP 1.8%,P=0.058)。
  • 第二恶性肿瘤所致死亡的10年累积发生率无差异(CHOP-RIT 7.1%对R-CHOP 3.2%,P=0.16),但MDS或AML所致死亡的累积发生率CHOP-RIT组高于R-CHOP组(4%对0.9%,P=0.02)。

临床怎么用

  • 作者认为,在替代方法的长期随访证明优效之前,免疫化疗应继续作为高危滤泡性淋巴瘤患者的标准诱导方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shadman M, Li H, Rimsza L, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. J Clin Oncol. 2018. PMID: 29356608. doi:10.1200/JCO.2017.74.5083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。